Target engagement in an alzheimer trial: Crenezumab l cerebrospinal fluid

Annals of Neurology

86, 215-224

DOI: 10.1002/ana.25513

Citation Report

#	Article	IF	Citations
1	Antibody-based therapies for Huntingtonâ€™s disease: current status and future directions. Neurobiology of Disease, 2019, 132, 104569.	2.1	17
2	Current and Emerging Pharmacological Targets for the Treatment of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 72, S145-S176.	1.2	26
3	Characterization of the selective in vitro and in vivo binding properties of crenezumab to oligomeric AÎ². Alzheimer's Research and Therapy, 2019, 11, 97.	3.0	22
4	Rationale for the development of an Alzheimerâ€™s disease vaccine. Human Vaccines and Immunotherapeutics, 2020, 16, 645-653.	1.4	16
5	The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis. Alzheimer's and Dementia, 2020, 16, 1553-1560.	0.4	165
6	Alzheimer's disease: Recent treatment strategies. European Journal of Pharmacology, 2020, 887, 173554.	1.7	300
7	Alzheimer's disease drug development pipeline: 2020. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12050.	1.8	353
8	Passive immunotherapies targeting AÎ² and tau in Alzheimer's disease. Neurobiology of Disease, 2020, 144, 105010.	2.1	81
9	Therapeutic Strategies to Reduce the Toxicity of Misfolded Protein Oligomers. International Journal of Molecular Sciences, 2020, 21, 8651.	1.8	23
10	Computational Investigation of Gantenerumab and Crenezumab Recognition of AÎ² Fibrils in Alzheimerâ€™s Disease Brain Tissue. ACS Chemical Neuroscience, 2020, 11, 3233-3244.	1.7	12
12	New therapeutics beyond amyloid-Î² and tau for the treatment of Alzheimerâ€™s disease. Acta Pharmacologica Sinica, 2021, 42, 1382-1389.	2.8	51
14	Rational design of a conformation-specific antibody for the quantification of AÎ² oligomers. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 13509-13518.	3.3	61
15	AMBAR, an Encouraging Alzheimer's Trial That Raises Questions. Frontiers in Neurology, 2020, 11, 459.	1.1	11
16	Perspective: Is therapeutic plasma exchange a viable option for treating Alzheimer's disease?. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12004.	1.8	7
17	Current and Future Treatments in Alzheimer Disease: An Update. Journal of Central Nervous System Disease, 2020, 12, 117957352090739.	0.7	413
18	Half a century of amyloids: past, present and future. Chemical Society Reviews, 2020, 49, 5473-5509.	18.7	345
19	Oligomers Are Promising Targets for Drug Development in the Treatment of Proteinopathies. Frontiers in Molecular Neuroscience, 2019, 12, 319.	1.4	15
20	Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 16.	3.0	31

#	Article	IF	Citations
21	Î²-amyloid: The known unknowns. Ageing Research Reviews, 2021, 65, 101212.	5.0	27
22	The Pathogenesis Mechanism, Structure Properties, Potential Drugs and Therapeutic Nanoparticles against the Small Oligomers of Amyloid-Î². Current Topics in Medicinal Chemistry, 2021, 21, 151-167.	1.0	5
23	Alzheimer's disease neuropathology is exacerbated following traumatic brain injury. Neuroprotection by co-administration of nanowired mesenchymal stem cells and cerebrolysin with monoclonal antibodies to amyloid beta peptide. Progress in Brain Research, 2021, 265, 1-97.	0.9	8
24	Association of naturally occurring antibodies to Î²-amyloid with cognitive decline and cerebral amyloidosis in Alzheimerâ€™s disease. Science Advances, 2021, 7, .	4.7	26
25	Quantifying misfolded protein oligomers as drug targets and biomarkers in Alzheimer and Parkinson diseases. Nature Reviews Chemistry, 2021, 5, 277-294.	13.8	56
26	The Neurovascular Unit Dysfunction in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 2022.	1.8	65
27	Alzheimer Disease Clinical Trials Targeting Amyloid. Neurologist, 2021, 26, 52-61.	0.4	19
28	Quantification of N-terminal amyloid-Î² isoforms reveals isomers are the most abundant form of the amyloid-Î² peptide in sporadic Alzheimerâ€™s disease. Brain Communications, 2021, 3, fcab028.	1.5	25
29	The use of the cellular thermal shift assay for the detection of intracellular beta-site amyloid precursor protein cleaving enzyme-1 ligand binding. Molecular Biology Reports, 2021, 48, 2957-2962.	1.0	3
30	Repurposing Antihypertensive Drugs for the Management of Alzheimerâ€™s Disease. Current Medicinal Chemistry, 2021, 28, 1716-1730.	1.2	6
31	Fluid Biomarkers in Clinical Trials for Alzheimerâ€™s Disease: Current and Future Application. Journal of Alzheimer's Disease, 2021, 81, 19-32.	1.2	3
32	Immunotherapies for Neurodegenerative Diseases. Frontiers in Neurology, 2021, 12, 654739.	1.1	31
33	Safety, Tolerability, and Pharmacokinetics of Highâ€Volume Subcutaneous Crenezumab, With and Without Recombinant Human Hyaluronidase in Healthy Volunteers. Clinical Pharmacology and Therapeutics, 2021, 110, 1337-1348.	2.3	6
34	The Development of Pharmacological Therapies for Alzheimerâ€™s Disease. Neurology and Therapy, 2021, 10, 609-626.	1.4	10
36	An update on Alzheimer's disease: Immunotherapeutic agents, stem cell therapy and gene editing. Life Sciences, 2021, 282, 119790.	2.0	9
37	Aging-Dependent Mitophagy Dysfunction in Alzheimerâ€™s Disease. Molecular Neurobiology, 2021, 58, 2362-2378.	1.9	25
38	Salvianolic Acid B improves cognitive impairment by inhibiting neuroinflammation and decreasing AÎ² level in Porphyromonas gingivalis-infected mice. Aging, 2020, 12, 10117-10128.	1.4	19
39	Current Status of Drug Targets and Emerging Therapeutic Strategies in the Management of Alzheimer's Disease. Current Neuropharmacology, 2020, 18, 883-903.	1.4	17

#	Article	IF	Citations
40	Current Perspectives in the Management of Neurodegenerative Alzheimerâ€™s Disease: Preclinical and Clinical Status. , 2020, , 101-136.		0
42	An ultraâ€sensitive immunoassay detects and quantifies soluble AÎ² oligomers in human plasma. Alzheimer's and Dementia, 2022, 18, 1186-1202.	0.4	18
43	Out with the old, in with the new: Could plasma exchange be used to fill a therapeutic gap in neurology?. Journal of the Neurological Sciences, 2022, 432, 120056.	0.3	3
44	The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nature Reviews Drug Discovery, 2022, 21, 306-318.	21.5	273
45	Immunotherapeutic Approaches for the Treatment of Neurodegenerative Diseases: Challenges and Outcomes. CNS and Neurological Disorders - Drug Targets, 2021, 21, .	0.8	0
46	Bioactive human Alzheimer brain soluble AÎ²: pathophysiology and therapeutic opportunities. Molecular Psychiatry, 2022, 27, 3182-3191.	4.1	14
47	Shared pathophysiology: Understanding stroke and Alzheimerâ€™s disease. Clinical Neurology and Neurosurgery, 2022, 218, 107306.	0.6	9
48	Physiological Roles of Monomeric Amyloid-Î² and Implications for Alzheimerâ€™s Disease Therapeutics. Experimental Neurobiology, 2022, 31, 65-88.	0.7	21
49	Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimerâ€™s Disease: Towards a Personalized Polypharmacology Patient-Centered Approach. International Journal of Molecular Sciences, 2022, 23, 9305.	1.8	13
50	Should we lower or raise levels of amyloid-Î² in the brains of Alzheimer patients?. Pharmacological Research, 2022, 183, 106390.	3.1	3
51	The Immune System as a Therapeutic Target for Alzheimerâ€™s Disease. Life, 2022, 12, 1440.	1.1	6
52	Proteinopathies: Deciphering Physiology and Mechanisms to Develop Effective Therapies for Neurodegenerative Diseases. Molecular Neurobiology, 2022, 59, 7513-7540.	1.9	5
53	Conformational Essentials Responsible for Neurotoxicity of AÎ²42 Aggregates Revealed by Antibodies against Oligomeric AÎ²42. Molecules, 2022, 27, 6751.	1.7	4
54	An update on the novel and approved drugs for Alzheimer disease. Saudi Pharmaceutical Journal, 2022, 30, 1755-1764.	1.2	19
55	Investigational treatments for neurodegenerative diseases caused by inheritance of gene mutations: lessons from recent clinical trials. Neural Regeneration Research, 2023, .	1.6	0
56	Role of Tau in Various Tauopathies, Treatment Approaches, and Emerging Role of Nanotechnology in Neurodegenerative Disorders. Molecular Neurobiology, 2023, 60, 1690-1720.	1.9	11
57	Lecanamab Ushers in a New Era of Antiâ€Amyloid Therapy for Alzheimer's Disease. Annals of Neurology, 2023, 93, 877-880.	2.8	3
60	Recent developments in the chemical biology of amyloid-Î² oligomer targeting. Organic and Biomolecular Chemistry, 2023, 21, 4540-4552.	1.5	5

#	Article	IF	Citations